8-KItem 7.01 · Reg FD Disclosure
Elevance reaffirms 2026 earnings and benefit expense ratio guidance
Filed with the SEC on · Summarized by InvestorsBot
Elevance Health reaffirmed its full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share, including about $6.90 per share in net unfavorable items, and adjusted earnings guidance of at least $27.00 per diluted share. The company also reaffirmed its 2026 benefit expense ratio target of 90.2%, plus or minus 50 basis points, during investor meetings planned over the next several weeks.